Embecta Corp. (NASDAQ: EMBC) Stock Competitors & Peer Comparison
See EMBC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for EMBC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EMBC | $5.91 | -0.67% | 350.6M | 2.27 | $2.60 | +5.28% |
| ISRG | $414.52 | +2.41% | 146.4B | 43.09 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.20% |
| BDX | $180.16 | -0.08% | 49.6B | 13.86 | $13.00 | +2.20% |
| RMD | $225.98 | +2.40% | 32.8B | 20.98 | $10.77 | +1.09% |
| MDLN | $35.45 | -0.28% | 30B | 25.98 | $1.36 | N/A |
| WST | $366.48 | -1.65% | 25.8B | 43.11 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $85.88 | -1.33% | 14.9B | 12.09 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.20% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
EMBC vs ISRG Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, ISRG has a market cap of 146.4B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while ISRG trades at $414.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas ISRG's P/E ratio is 43.09. In terms of profitability, EMBC's ROE is -0.14%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, EMBC is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
EMBC vs BDXA Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas BDXA's P/E ratio is 45.70. In terms of profitability, EMBC's ROE is -0.14%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, EMBC is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
EMBC vs BDX Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, BDX has a market cap of 49.6B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while BDX trades at $180.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas BDX's P/E ratio is 13.86. In terms of profitability, EMBC's ROE is -0.14%, compared to BDX's ROE of +0.04%. Regarding short-term risk, EMBC is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
EMBC vs RMD Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, RMD has a market cap of 32.8B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while RMD trades at $225.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas RMD's P/E ratio is 20.98. In terms of profitability, EMBC's ROE is -0.14%, compared to RMD's ROE of +0.24%. Regarding short-term risk, EMBC is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
EMBC vs MDLN Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, MDLN has a market cap of 30B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while MDLN trades at $35.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas MDLN's P/E ratio is 25.98. In terms of profitability, EMBC's ROE is -0.14%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, EMBC is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
EMBC vs WST Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, WST has a market cap of 25.8B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while WST trades at $366.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas WST's P/E ratio is 43.11. In terms of profitability, EMBC's ROE is -0.14%, compared to WST's ROE of +0.19%. Regarding short-term risk, EMBC is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
EMBC vs HOLX Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas HOLX's P/E ratio is 31.54. In terms of profitability, EMBC's ROE is -0.14%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, EMBC is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
EMBC vs SOLV Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, SOLV has a market cap of 14.9B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while SOLV trades at $85.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas SOLV's P/E ratio is 12.09. In terms of profitability, EMBC's ROE is -0.14%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, EMBC is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
EMBC vs BDXB Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas BDXB's P/E ratio is 7.60. In terms of profitability, EMBC's ROE is -0.14%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, EMBC is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
EMBC vs BAX Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, BAX has a market cap of 12.4B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while BAX trades at $23.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas BAX's P/E ratio is 11.52. In terms of profitability, EMBC's ROE is -0.14%, compared to BAX's ROE of -0.17%. Regarding short-term risk, EMBC is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
EMBC vs COO Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, COO has a market cap of 10.7B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while COO trades at $54.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas COO's P/E ratio is 12.01. In terms of profitability, EMBC's ROE is -0.14%, compared to COO's ROE of +0.07%. Regarding short-term risk, EMBC is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check COO's competition here
Avantor, Inc. (NYSE: AVTR)
EMBC vs AVTR Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while AVTR trades at $15.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas AVTR's P/E ratio is 18.05. In terms of profitability, EMBC's ROE is -0.14%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, EMBC is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
EMBC vs RGEN Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, RGEN has a market cap of 9.5B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while RGEN trades at $167.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas RGEN's P/E ratio is 93.14. In terms of profitability, EMBC's ROE is -0.14%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, EMBC is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
EMBC vs ATR Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, ATR has a market cap of 7.7B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while ATR trades at $120.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas ATR's P/E ratio is 21.05. In terms of profitability, EMBC's ROE is -0.14%, compared to ATR's ROE of +0.14%. Regarding short-term risk, EMBC is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
EMBC vs BLCO Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while BLCO trades at $17.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas BLCO's P/E ratio is 26.68. In terms of profitability, EMBC's ROE is -0.14%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, EMBC is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
EMBC vs TFX Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, TFX has a market cap of 5.5B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while TFX trades at $124.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas TFX's P/E ratio is 14.23. In terms of profitability, EMBC's ROE is -0.14%, compared to TFX's ROE of -0.32%. Regarding short-term risk, EMBC is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check TFX's competition here
Stevanato Group S.p.A. (NYSE: STVN)
EMBC vs STVN Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, STVN has a market cap of 5.3B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while STVN trades at $19.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas STVN's P/E ratio is 29.44. In terms of profitability, EMBC's ROE is -0.14%, compared to STVN's ROE of +0.09%. Regarding short-term risk, EMBC is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
EMBC vs MMSI Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while MMSI trades at $85.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas MMSI's P/E ratio is 21.76. In terms of profitability, EMBC's ROE is -0.14%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, EMBC is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
EMBC vs ICUI Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while ICUI trades at $156.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas ICUI's P/E ratio is 19.48. In terms of profitability, EMBC's ROE is -0.14%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, EMBC is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
EMBC vs NVST Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, NVST has a market cap of 3.7B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while NVST trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas NVST's P/E ratio is 15.67. In terms of profitability, EMBC's ROE is -0.14%, compared to NVST's ROE of +0.03%. Regarding short-term risk, EMBC is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
EMBC vs PLSE Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, PLSE has a market cap of 3.4B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while PLSE trades at $49.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas PLSE's P/E ratio is -41.60. In terms of profitability, EMBC's ROE is -0.14%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, EMBC is more volatile compared to PLSE. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
EMBC vs ATRC Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, ATRC has a market cap of 2.7B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while ATRC trades at $53.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas ATRC's P/E ratio is 1655.59. In terms of profitability, EMBC's ROE is -0.14%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, EMBC is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
EMBC vs BLFS Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, BLFS has a market cap of 1.9B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while BLFS trades at $38.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas BLFS's P/E ratio is 37.49. In terms of profitability, EMBC's ROE is -0.14%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, EMBC is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check BLFS's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
EMBC vs LMAT Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while LMAT trades at $79.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas LMAT's P/E ratio is 29.16. In terms of profitability, EMBC's ROE is -0.14%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, EMBC is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check LMAT's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
EMBC vs XRAY Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, XRAY has a market cap of 1.7B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while XRAY trades at $8.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas XRAY's P/E ratio is 5.97. In terms of profitability, EMBC's ROE is -0.14%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, EMBC is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check XRAY's competition here
Azenta, Inc. (NASDAQ: AZTA)
EMBC vs AZTA Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, AZTA has a market cap of 1.7B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while AZTA trades at $35.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas AZTA's P/E ratio is 85.45. In terms of profitability, EMBC's ROE is -0.14%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, EMBC is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
EMBC vs KMTS Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while KMTS trades at $26.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas KMTS's P/E ratio is -10.00. In terms of profitability, EMBC's ROE is -0.14%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, EMBC is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
EMBC vs STAA Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while STAA trades at $22.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas STAA's P/E ratio is 39.23. In terms of profitability, EMBC's ROE is -0.14%, compared to STAA's ROE of +0.01%. Regarding short-term risk, EMBC is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
EMBC vs ATRI Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas ATRI's P/E ratio is 64.50. In terms of profitability, EMBC's ROE is -0.14%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, EMBC is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
EMBC vs ANGO Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, ANGO has a market cap of 586.5M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while ANGO trades at $14.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas ANGO's P/E ratio is -36.38. In terms of profitability, EMBC's ROE is -0.14%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, EMBC is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check ANGO's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
EMBC vs SMTI Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, SMTI has a market cap of 322.2M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while SMTI trades at $35.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas SMTI's P/E ratio is -584.17. In terms of profitability, EMBC's ROE is -0.14%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, EMBC is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
EMBC vs OSUR Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, OSUR has a market cap of 256.8M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while OSUR trades at $3.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas OSUR's P/E ratio is -5.41. In terms of profitability, EMBC's ROE is -0.14%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, EMBC is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
EMBC vs UTMD Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, UTMD has a market cap of 233.9M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while UTMD trades at $73.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas UTMD's P/E ratio is 21.73. In terms of profitability, EMBC's ROE is -0.14%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, EMBC is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check UTMD's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
EMBC vs NNNN Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, NNNN has a market cap of 215.1M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while NNNN trades at $4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas NNNN's P/E ratio is 32.67. In terms of profitability, EMBC's ROE is -0.14%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, EMBC is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check NNNN's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
EMBC vs PDEX Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, PDEX has a market cap of 200.5M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while PDEX trades at $62.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas PDEX's P/E ratio is 15.21. In terms of profitability, EMBC's ROE is -0.14%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, EMBC is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
EMBC vs KRMD Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, KRMD has a market cap of 136.9M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while KRMD trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas KRMD's P/E ratio is -74.50. In terms of profitability, EMBC's ROE is -0.14%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, EMBC is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
EMBC vs STXS Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, STXS has a market cap of 111.2M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while STXS trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas STXS's P/E ratio is -6.68. In terms of profitability, EMBC's ROE is -0.14%, compared to STXS's ROE of -1.33%. Regarding short-term risk, EMBC is more volatile compared to STXS. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
EMBC vs AKYA Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas AKYA's P/E ratio is -1.34. In terms of profitability, EMBC's ROE is -0.14%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, EMBC is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
EMBC vs DXR Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, DXR has a market cap of 61.4M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while DXR trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas DXR's P/E ratio is 8.55. In terms of profitability, EMBC's ROE is -0.14%, compared to DXR's ROE of +0.13%. Regarding short-term risk, EMBC is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
EMBC vs STSS Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas STSS's P/E ratio is -0.02. In terms of profitability, EMBC's ROE is -0.14%, compared to STSS's ROE of -1.54%. Regarding short-term risk, EMBC is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
EMBC vs OMIC Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas OMIC's P/E ratio is -0.58. In terms of profitability, EMBC's ROE is -0.14%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, EMBC is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
EMBC vs IGAP Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas IGAP's P/E ratio is -10.52. In terms of profitability, EMBC's ROE is -0.14%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, EMBC is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check IGAP's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
EMBC vs POCI Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, POCI has a market cap of 49.5M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while POCI trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas POCI's P/E ratio is -9.83. In terms of profitability, EMBC's ROE is -0.14%, compared to POCI's ROE of -0.24%. Regarding short-term risk, EMBC is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check POCI's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
EMBC vs HBIO Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, HBIO has a market cap of 38.3M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while HBIO trades at $8.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas HBIO's P/E ratio is -23.61. In terms of profitability, EMBC's ROE is -0.14%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, EMBC is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check HBIO's competition here
Nephros, Inc. (NASDAQ: NEPH)
EMBC vs NEPH Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, NEPH has a market cap of 34.7M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while NEPH trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas NEPH's P/E ratio is 53.33. In terms of profitability, EMBC's ROE is -0.14%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, EMBC is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
EMBC vs MLSS Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, MLSS has a market cap of 33.3M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while MLSS trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas MLSS's P/E ratio is -7.54. In terms of profitability, EMBC's ROE is -0.14%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, EMBC is more volatile compared to MLSS. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
EMBC vs SDC Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas SDC's P/E ratio is -0.03. In terms of profitability, EMBC's ROE is -0.14%, compared to SDC's ROE of -1.96%. Regarding short-term risk, EMBC is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
EMBC vs IVC Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas IVC's P/E ratio is -0.79. In terms of profitability, EMBC's ROE is -0.14%, compared to IVC's ROE of -0.46%. Regarding short-term risk, EMBC is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
EMBC vs RVP Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, RVP has a market cap of 20.5M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while RVP trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas RVP's P/E ratio is -5.69. In terms of profitability, EMBC's ROE is -0.14%, compared to RVP's ROE of -0.05%. Regarding short-term risk, EMBC is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
EMBC vs BNGO Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, BNGO has a market cap of 16.8M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while BNGO trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas BNGO's P/E ratio is -0.48. In terms of profitability, EMBC's ROE is -0.14%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, EMBC is more volatile compared to BNGO. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
EMBC vs ZJYL Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, ZJYL has a market cap of 16.6M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while ZJYL trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas ZJYL's P/E ratio is 14.50. In terms of profitability, EMBC's ROE is -0.14%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, EMBC is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
EMBC vs RGNT Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, RGNT has a market cap of 11.4M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while RGNT trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas RGNT's P/E ratio is -0.66. In terms of profitability, EMBC's ROE is -0.14%, compared to RGNT's ROE of N/A. Regarding short-term risk, EMBC is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check RGNT's competition here
Femasys Inc. (NASDAQ: FEMY)
EMBC vs FEMY Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, FEMY has a market cap of 6M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while FEMY trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas FEMY's P/E ratio is -0.45. In terms of profitability, EMBC's ROE is -0.14%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, EMBC is more volatile compared to FEMY. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
EMBC vs LUCY Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, LUCY has a market cap of 5.7M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while LUCY trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas LUCY's P/E ratio is -0.71. In terms of profitability, EMBC's ROE is -0.14%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, EMBC is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check LUCY's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
EMBC vs CUPR Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, CUPR has a market cap of 5.1M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while CUPR trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas CUPR's P/E ratio is -1.38. In terms of profitability, EMBC's ROE is -0.14%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, EMBC is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check CUPR's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
EMBC vs NSTG Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas NSTG's P/E ratio is -0.03. In terms of profitability, EMBC's ROE is -0.14%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, EMBC is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
EMBC vs POAI Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas POAI's P/E ratio is -0.38. In terms of profitability, EMBC's ROE is -0.14%, compared to POAI's ROE of -21.19%. Regarding short-term risk, EMBC is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
EMBC vs MHUA Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas MHUA's P/E ratio is 0.25. In terms of profitability, EMBC's ROE is -0.14%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, EMBC is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
EMBC vs GMVD Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas GMVD's P/E ratio is -0.01. In terms of profitability, EMBC's ROE is -0.14%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, EMBC is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
EMBC vs GMVDW Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas GMVDW's P/E ratio is N/A. In terms of profitability, EMBC's ROE is -0.14%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, EMBC is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
EMBC vs AVGR Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas AVGR's P/E ratio is -0.05. In terms of profitability, EMBC's ROE is -0.14%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, EMBC is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
EMBC vs NXGL Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, NXGL has a market cap of 1.5M. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while NXGL trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas NXGL's P/E ratio is -0.25. In terms of profitability, EMBC's ROE is -0.14%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, EMBC is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check NXGL's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
EMBC vs NXGLW Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, NXGLW has a market cap of 775.4K. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas NXGLW's P/E ratio is -0.01. In terms of profitability, EMBC's ROE is -0.14%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, EMBC is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
EMBC vs LUCYW Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas LUCYW's P/E ratio is N/A. In terms of profitability, EMBC's ROE is -0.14%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, EMBC is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for EMBC.Check LUCYW's competition here
Invuity, Inc. (NASDAQ: IVTY)
EMBC vs IVTY Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas IVTY's P/E ratio is -3.80. In terms of profitability, EMBC's ROE is -0.14%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, EMBC is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
EMBC vs HRC Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, HRC has a market cap of 0. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas HRC's P/E ratio is 41.92. In terms of profitability, EMBC's ROE is -0.14%, compared to HRC's ROE of +0.14%. Regarding short-term risk, EMBC is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check HRC's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
EMBC vs ATRS Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas ATRS's P/E ratio is 14.95. In terms of profitability, EMBC's ROE is -0.14%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, EMBC is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check ATRS's competition here
Analogic Corporation (NASDAQ: ALOG)
EMBC vs ALOG Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas ALOG's P/E ratio is 40.93. In terms of profitability, EMBC's ROE is -0.14%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, EMBC is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check ALOG's competition here
IntriCon Corporation (NASDAQ: IIN)
EMBC vs IIN Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, IIN has a market cap of 0. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas IIN's P/E ratio is 226.45. In terms of profitability, EMBC's ROE is -0.14%, compared to IIN's ROE of -0.00%. Regarding short-term risk, EMBC is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check IIN's competition here
Apria, Inc. (NASDAQ: APR)
EMBC vs APR Comparison October 2026
Embecta Corp. (NASDAQ: EMBC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMBC stands at 350.6M. In comparison, APR has a market cap of 0. Regarding current trading prices, EMBC is priced at $5.91 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMBC currently has a P/E ratio of 2.27, whereas APR's P/E ratio is 22.59. In terms of profitability, EMBC's ROE is -0.14%, compared to APR's ROE of +9.81%. Regarding short-term risk, EMBC is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for EMBC.Check APR's competition here